Recent investigations on retatrutides, a dual agonist for incretin hormone and GIP, suggest significant results in managing weight gain and type 2 diabetes. Early data from clinical read more trials show notable diminutions in body bulk and enhanced glucose control. Ongoing research is focused on long-term safety and efficacy, as well as anticipate